{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:52:21Z","timestamp":1790621541056,"version":"4.1.0"},"reference-count":28,"publisher":"Impact Journals, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,2,21]]},"DOI":"10.18632\/oncotarget.14712","type":"journal-article","created":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T15:42:20Z","timestamp":1484840540000},"page":"13030-13038","source":"Crossref","is-referenced-by-count":32,"title":["Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis"],"prefix":"10.18632","volume":"8","author":[{"given":"Dongxu","family":"Pei","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Hennan Province Hospital of TCM, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hennan Province Hospital of TCM, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hennan Province Hospital of TCM, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hennan Province Hospital of TCM, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hennan Province Hospital of TCM, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hennan Province Hospital of TCM, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Anyang Hospital of Traditional Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,1,18]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bcp.2016.07.012","article-title":"New therapeutic strategies for malignant pleural mesothelioma","volume":"123","author":"Alfieri","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/1753465816628800","article-title":"Malignant pleural mesothelioma: an update on diagnosis and treatment options","volume":"10","author":"Nowak","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"3","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Lake","year":"2005","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Lake","year":"2005","journal-title":"Lancet"},{"key":"5","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1055\/s-0035-1549449","article-title":"Asbestos-related lung cancer and malignant mesothelioma of the pleura: selected current issues","volume":"36","author":"Markowitz","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"6","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Paoletti","year":"2003","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrm1130","article-title":"Fibulins: a versatile family of extracellular matrix proteins","volume":"4","author":"Chu","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8","doi-asserted-by":"crossref","first-page":"11805","DOI":"10.1074\/jbc.M611029200","article-title":"A comparative analysis of the fibulin protein family. Biochemical characterization, binding interactions, and tissue localization","volume":"282","author":"Sasaki","year":"2007","journal-title":"J Biol Chem"},{"key":"9","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.7314\/APJCP.2015.16.4.1403","article-title":"Fibulin-3 as a Diagnostic Biomarker in Patients with Malignant Mesothelioma","volume":"16","author":"Senyigit","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"10","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Robinson","year":"2014","journal-title":"Thorax"},{"key":"11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2217\/fon.15.317","article-title":"Biomarkers and prognostic factors for malignant pleural mesothelioma","volume":"11","author":"Stella","year":"2015","journal-title":"Future Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Liu","year":"2012","journal-title":"N Engl J Med"},{"key":"13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ctrv.2015.05.001","article-title":"The established and future biomarkers of malignant pleural mesothelioma","volume":"41","author":"Roe","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"14","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-15-1130","article-title":"HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients","volume":"22","author":"Yang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/bjc.2015.286","article-title":"Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis","volume":"113","author":"Vallely","year":"2015","journal-title":"Br J Cancer"},{"key":"16","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/bjc.2015.62","article-title":"The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication","volume":"112","author":"Arnold","year":"2015","journal-title":"Br J Cancer"},{"key":"17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00408-016-9868-1","article-title":"Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure","volume":"194","author":"Senyigit","year":"2016","journal-title":"Lung"},{"key":"18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MCP.0000000000000167","article-title":"Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma","volume":"21","author":"Robinson","year":"2015","journal-title":"Curr Opin Pulm Med"},{"key":"19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1515\/raon-2015-0019","article-title":"Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma","volume":"49","author":"Franko","year":"2015","journal-title":"Radiol Oncol"},{"issue":"155","key":"20","first-page":"529","article-title":"QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"2011","author":"Bossuyt","journal-title":"Ann Intern Med"},{"key":"21","unstructured":"Wells BS, O'Connell, Peterson, Welch, M Losos. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. URL: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"22","doi-asserted-by":"publisher","first-page":"25791","DOI":"10.18632\/oncotarget.8268","article-title":"Long noncoding RNAs as auxiliary biomarkers for gastric cancer screening: A pooled analysis of individual studies","volume":"7","author":"Zheng","year":"2016","journal-title":"Oncotarget"},{"issue":"61","key":"23","first-page":"1471","article-title":"PAX1 Methylation Hallmarks Promising Accuracy for Cervical Cancer Screening in Asians: Results from a Meta-Analysis","volume":"2015","author":"Zhang","journal-title":"Clin Lab"},{"key":"24","doi-asserted-by":"crossref","first-page":"e41561","DOI":"10.1371\/journal.pone.0041561","article-title":"Comparing the MicroRNA spectrum between serum and plasma","volume":"7","author":"Galas","year":"2012","journal-title":"PloS one"},{"key":"25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2288-6-31","article-title":"Meta-DiSc: a software for meta-analysis of test accuracy data","volume":"6","author":"Coomarasamy","year":"2006","journal-title":"BMC Med Res Methodol"},{"key":"26","first-page":"587","article-title":"Diagnostic accuracy of Golgi protein 73 in primary hepatic carcinoma using ELISA: a systematic review and meta-analysis","volume":"60","author":"Bao","year":"2014","journal-title":"Clin Lab"},{"key":"27","first-page":"1101","article-title":"MicroRNAs as Biomarkers for the Diagnostics of Bladder Cancer: a Meta-Analysis","volume":"61","author":"Lan","year":"2015","journal-title":"Clin Lab"},{"key":"28","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Altman","year":"2009","journal-title":"J Clin Epidemiol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T16:47:18Z","timestamp":1589129238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,18]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,2,21]]}},"alternative-id":["14712","28103581"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.14712","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,18]]}}}